{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PBC&page=2", "query": { "condition": "PBC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PBC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T13:35:28.433Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04620733", "title": "RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Seladelpar 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Seladelpar 5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 193, "start_date": "2021-04-21", "completion_date": "2023-08-11", "has_results": true, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 40, "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04620733" }, { "nct_id": "NCT06051617", "title": "Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Seladelpar", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 318, "start_date": "2023-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Lancaster, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051617" }, { "nct_id": "NCT05239468", "title": "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Bezafibrate 100 mg", "type": "DRUG" }, { "name": "Bezafibrate 200 mg", "type": "DRUG" }, { "name": "Obeticholic Acid 5 mg", "type": "DRUG" }, { "name": "Obeticholic Acid placebo", "type": "DRUG" }, { "name": "Bezafibrate Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-03-21", "completion_date": "2025-09-01", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239468" }, { "nct_id": "NCT01473524", "title": "Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cirrhosis" ], "interventions": [ { "name": "Obeticholic Acid (OCA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2012-01", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 15, "location_summary": "Sacramento, California • San Diego, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473524" }, { "nct_id": "NCT06525311", "title": "A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Biliary Cholangitis", "Compensated Cirrhosis" ], "interventions": [ { "name": "K-808", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kowa Research Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-10-01", "completion_date": "2025-04-09", "has_results": false, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 6, "location_summary": "Chandler, Arizona • Coronado, California • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06525311" }, { "nct_id": "NCT02026401", "title": "Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cirrhosis" ], "interventions": [ { "name": "NGM282", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 45, "start_date": "2014-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02026401" }, { "nct_id": "NCT03155932", "title": "Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "APD334", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arena Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2017-12-29", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2022-03-24", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 4, "location_summary": "Sacramento, California • Houston, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155932" }, { "nct_id": "NCT01389973", "title": "A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cirrhosis" ], "interventions": [ { "name": "ustekinumab 90 mg", "type": "DRUG" }, { "name": "ustekinumab 45 mg", "type": "DRUG" }, { "name": "ustekinumab 180 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2011-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2016-06-20", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 6, "location_summary": "Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Tupelo", "state": "Mississippi" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01389973" }, { "nct_id": "NCT00058903", "title": "Treatment of Cholestatic Pruritus With Sertraline", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pruritus", "Liver Cirrhosis, Biliary", "Hepatitis C" ], "interventions": [ { "name": "sertraline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2003-04", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2010-01-13", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058903" }, { "nct_id": "NCT07631442", "title": "Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Biliary Cholangitis (PBC)" ], "interventions": [], "intervention_types": [], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-07", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-26T13:35:28.433Z", "location_count": 1, "location_summary": "Redwood City, California", "locations": [ { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07631442" } ] }